The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Exclusion Criteria

• •Participation in an investigational program with interventions outside of clinical routine practice
• •Contraindications as listed in the local intravitreal aflibercept 8 mg local product information
• •Extra/periocular infection or inflammation in either eye at time of first injection
• •Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
• •Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
• •Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months
• •Fluocinolone implant in the study eye within the last 3 years
• •Dexamethasone implant in the study eye within the last 6 months
• •Any concurrent drug releasing implant in the study eye
• •Participation in an investigational program with interventions outside of clinical routine practice
• •Contraindications as listed in the intravitreal aflibercept 8 mg local product information
• •Extra/periocular infection or inflammation in either eye at time of first injection
• •Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
• •Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information
• •Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
• •Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months
• •Fluocinolone implant in the study eye within the last 3 years
• •Dexamethasone implant in the study eye within the last 6 months
• •Any concurrent drug releasing implant in the study eye